April 3 (Reuters) - Akebia Therapeutics Inc AKBA.O:
AKEBIA THERAPEUTICS ANNOUNCES POSITIVE OPINION OF EUROPEAN MEDICINES AGENCY FOR XOANACYL®, AN ORAL THERAPY FOR CHRONIC KIDNEY DISEASE LICENSED TO AVEROA
AKEBIA THERAPEUTICS: EC WILL REVIEW CHMP RECOMMENDATION, FINAL DECISION EXPECTED IN ABOUT TWO MONTHS
Source text: ID:nGNX4P6T4q
Further company coverage: AKBA.O
(((( Reuters.briefs@thomsonreuters.com ;));))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。